May 2, 2017 7:00am EDT Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use
Apr 17, 2017 7:00am EDT Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update
Apr 13, 2017 11:30am EDT Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
Apr 11, 2017 7:00am EDT Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder
Apr 3, 2017 7:00am EDT Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Mar 30, 2017 8:01am EDT Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock
Mar 29, 2017 7:00am EDT Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference
Mar 28, 2017 7:00am EDT Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL
